Singapore, Sept. 28 -- United Immunity, a clinical stage biotechnology company, has raised a total of Euro2.2 billion in private financing, comprising Euro1.8 billion through a third-party allotment of new shares and Euro0.4 billion through debt financing.

In addition, the company's project, "Development of in vivo CAR-Macrophage Therapy for Refractory Solid Tumours," has been selected for the Strengthening Programme for Pharmaceutical Startup Ecosystem (V-eco) of the Japan Agency for Medical Research and Development (AMED).

By combining the Euro2.2 billion in private financing raised in this round with up to approximately Euro2.8 billion in public grant funding, the company expects to have access to up to Euro5.0 billion in total devel...